NewcelX (Drug Discovery) Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
- Investors
-
4
NewcelX (Drug Discovery) General Information
Description
Developer of clinical-stage biopharmaceutical therapies designed for rare and complex central nervous system disorders. The company's lead candidates utilize proprietary extended-release formulations and triple monoamine reuptake inhibition, providing patients with narcolepsy and ADHD with innovative treatment options to address unmet medical needs in sleep and neurodevelopmental disorders.
Contact Information
Website
www.nlspharma.comCorporate Office
- The Circle 6
- P.O. Box
- 8058 Zurich
- Switzerland
Corporate Office
- The Circle 6
- P.O. Box
- 8058 Zurich
- Switzerland
NewcelX (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 30-Oct-2025 | Completed | Generating Revenue | |||
| 13. PIPE | 27-Jun-2025 | Completed | Generating Revenue | |||
| 12. PIPE | 04-Dec-2024 | Completed | Generating Revenue | |||
| 11. PIPE | 01-Dec-2024 | Completed | Generating Revenue | |||
| 10. PIPE | 21-Oct-2024 | Completed | Generating Revenue | |||
| 9. PIPE | 11-Oct-2024 | Completed | Generating Revenue | |||
| 8. 2PO | 01-Jul-2024 | Completed | Generating Revenue | |||
| 7. PIPE | 22-Mar-2024 | Completed | Generating Revenue | |||
| 6. PIPE | 14-Dec-2022 | $10M | $58.9M | Completed | Generating Revenue | |
| 5. PIPE | 10-Oct-2022 | $4M | $48.9M | Completed | Generating Revenue |
NewcelX (Drug Discovery) Comparisons
Industry
Financing
Details
NewcelX (Drug Discovery) Competitors (22)
One of NewcelX (Drug Discovery)’s 22 competitors is Gesynta Pharma, a Venture Capital-Backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| MindImmune | Venture Capital-Backed | Kingston, RI | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA |
NewcelX (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NewcelX (Drug Discovery) Patents
NewcelX (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4366735-A1 | Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndrome | Inactive | 08-Jul-2021 | ||
| US-20240316023-A1 | Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndrome | Pending | 08-Jul-2021 | ||
| WO-2023281103-A1 | Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndrome | Inactive | 08-Jul-2021 | ||
| JP-2024524605-A | Benezin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in the treatment of kleine-levin syndrome | Pending | 08-Jul-2021 | ||
| EP-4366714-A1 | Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) | Inactive | 08-Jul-2021 | A61K31/165 |
NewcelX (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NewcelX (Drug Discovery) Acquisitions (1)
NewcelX (Drug Discovery)’s most recent deal was a Merger/Acquisition with NewcelX. The deal was made on 30-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NewcelX | 30-Oct-2025 | Merger/Acquisition | Drug Delivery |
NewcelX (Drug Discovery) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
NewcelX (Drug Discovery) Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NewcelX | Kloten, Switzerland | 2009 |
NewcelX (Drug Discovery) FAQs
-
When was NewcelX (Drug Discovery) founded?
NewcelX (Drug Discovery) was founded in 2015.
-
Where is NewcelX (Drug Discovery) headquartered?
NewcelX (Drug Discovery) is headquartered in Zurich, Switzerland.
-
What is the size of NewcelX (Drug Discovery)?
NewcelX (Drug Discovery) has 4 total employees.
-
What industry is NewcelX (Drug Discovery) in?
NewcelX (Drug Discovery)’s primary industry is Drug Discovery.
-
Is NewcelX (Drug Discovery) a private or public company?
NewcelX (Drug Discovery) is a Private company.
-
What is NewcelX (Drug Discovery)’s current revenue?
The current revenue for NewcelX (Drug Discovery) is .
-
How much funding has NewcelX (Drug Discovery) raised over time?
NewcelX (Drug Discovery) has raised $80M.
-
Who are NewcelX (Drug Discovery)’s competitors?
Gesynta Pharma, Harmony Biosciences Holdings, MindImmune, Gilead, and Cardurion are some of the 22 competitors of NewcelX (Drug Discovery).
-
When was NewcelX (Drug Discovery) acquired?
NewcelX (Drug Discovery) was acquired on 30-Oct-2025.
-
Who acquired NewcelX (Drug Discovery)?
NewcelX (Drug Discovery) was acquired by NewcelX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
